Pre-procedural Atorvastatin mobilizes endothelial progenitor cells: Clues to the salutary effects of statins on healing of stented human arteries

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Hibbert, Benjamin ^a   Ma, Xiaoli ^a   Pourdjabbar, Ali ^a   Simard, Trevor ^a   Rayner, Katey ^a   Sun, Jiangfeng ^a   Chen, Yong Xiang ^a   Filion, Lionel ^b   O'Brien, Edward R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CELL ADHESION; CELL CULTURE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; AGED; ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; METHODOLOGY; MIDDLE AGED; REGENERATION; STEM CELL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANIMALIA;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICHOLESTEREMIC AGENTS; ARTERIES; CELL ADHESION; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; REGENERATION; STEM CELLS; STENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551569913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016413     Document Type: Article

References (44)

1. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, et al. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020-9.
2. Zampetaki A, Kirton JP, Xu Q (2008) Vascular repair by endothelial progenitor cells. Cardiovasc Res 78: 413-21.
3. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600.
4. George J, Herz I, Goldstein E, Abashidze S, Deutch V, et al. (2003) Number and adhesive properties of circulating endothelial progenitor cells in patients with instent restenosis. Arterioscler Thromb Vasc Biol 23: e57-e60.
5. Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, et al. (2004) Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 110: 2039-46.
6. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, et al. (2003) Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107: 3059-65.
7. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, et al. (2002) Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105: 3017-24.
8. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, et al. (2001) HMGCoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-7.
9. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, et al. (2001) HMGCoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399-405.
10. Schroeter MR, Humboldt T, Schafer K, Konstantinides S (2009) Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Atherosclerosis 205: 63-73.
11. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, et al. (2009) Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 54: 2290-5.
12. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5: 213-26.
13. Hirschi KK, Ingram DA, Yoder MC (2008) Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28: 1584-95.
14. Timmermans F, Van HF, De SM, Raedt R, Plasschaert F, et al. (2007) Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 27: 1572-9.
15. Bearzi C, Leri A, Lo MF, Rota M, Gonzalez A, et al. (2009) Identification of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci U S A 106: 15885-90.
16. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7.
17. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, et al. (2006) Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107: 3546-54.
18. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, et al. (2006) VEGFinduced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175-89.
19. Hibbert B, Ma X, Pourdjabbar A, Holm E, Rayner K, et al. (2009) Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res 83: 16-23.
20. Hibbert B, Chen YX, O'Brien ER (2004) c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol 287: H518-H524.
21. Ma X, Hibbert B, White D, Seymour R, Whitman SC, et al. (2008) Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation. PLoS One 3: e1894.
22. Ma X, Hibbert B, Dhaliwal B, Seibert T, Chen YX, et al. (2010) Delayed reendothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res 86: 338-45.
23. Hibbert B, Olsen S, O'Brien E (2003) Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med1 3: 322-6.
24. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, et al. (2008) Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 197: 496-503.
25. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, et al. (2003) HMGCoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92: 1049-55.
26. Deb A, Skelding KA, Wang S, Reeder M, Simper D, et al. (2004) Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation 110: 2673-7.
27. Beijk MA, Klomp M, Verouden NJ, van GN, Koch KT, et al. (2009) GenousTM endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J 31: 1055-64.
28. Banerjee S, Brilakis E, Zhang S, Roesle M, Lindsey J, et al. (2006) Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis 189: 70-5.
29. Padfield GJ, Newby DE, Mills NL (2010) Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 55: 1553-65.
30. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, et al. (2007) Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 115: 553-61.
31. Mills NL, Tura O, Padfield GJ, Millar C, Lang NN, et al. (2009) Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart 95: 2003-8.
32. Egan CG, Caporali F, Huqi AF, Zito MC, Focardi M, et al. (2009) Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: kinetics following percutaneous coronary intervention and association with clinical characteristics. Thromb Haemost 101: 1138-46.
33. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, et al. (2001) Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103: 2885-90.
34. Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschope C, Schultheiss HP, et al. (2010) Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS One 5: e13790.
35. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, et al. (2007) Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 192: 413-20.
36. Deschaseaux F, Selmani Z, Falcoz PE, Mersin N, Meneveau N, et al. (2007) Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors. Eur J Pharmacol 562: 111-8.
37. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, et al. (2004) Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24: 1442-7.
38. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, et al. (2006) Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol 41: 34-43.
39. Werner C, Kamani CH, Gensch C, Bohm M, Laufs U (2007) The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56: 2609-15.
40. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, et al. (2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110: 674-8.
41. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49: 1272-8.
42. Di SG, Patti G, Pasceri V, Gaspardone A, Colonna G, et al. (2009) Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54: 558-65.
43. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-48.
44. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-407.